AI generated summary of Pubmed citation/abstract with PMID 38091577

https://pubmed.ncbi.nlm.nih.gov/38091577

This study found that ibrutinib used as a first-line treatment for marginal zone lymphoma in a real-world setting in the USA showed promising outcomes, with high response rates and overall survival.